ECSP088123A - Anticoncepcion oral con trimegestona - Google Patents

Anticoncepcion oral con trimegestona

Info

Publication number
ECSP088123A
ECSP088123A EC2008008123A ECSP088123A ECSP088123A EC SP088123 A ECSP088123 A EC SP088123A EC 2008008123 A EC2008008123 A EC 2008008123A EC SP088123 A ECSP088123 A EC SP088123A EC SP088123 A ECSP088123 A EC SP088123A
Authority
EC
Ecuador
Prior art keywords
trimegestone
oral contraception
contraception
successive days
oral
Prior art date
Application number
EC2008008123A
Other languages
English (en)
Inventor
Mann Heinrich Kugel
Oliver Gloger
Maria Popova
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37575731&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088123(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of ECSP088123A publication Critical patent/ECSP088123A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a un método para la anticoncepción que comprende la administración de trimegestona junto con etinilestradiol a una mujer en edad fértil en al menos 21 días sucesivos, comenzando el día 1 del ciclo menstrual, en el que en al menos uno de los al menos 21 días sucesivos la dosis diaria de trimegestona es superior a 500 ug.
EC2008008123A 2005-07-20 2008-01-18 Anticoncepcion oral con trimegestona ECSP088123A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005034498A DE102005034498A1 (de) 2005-07-20 2005-07-20 Orale Kontrazeption mit Trimegeston

Publications (1)

Publication Number Publication Date
ECSP088123A true ECSP088123A (es) 2008-02-20

Family

ID=37575731

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008123A ECSP088123A (es) 2005-07-20 2008-01-18 Anticoncepcion oral con trimegestona

Country Status (13)

Country Link
US (3) US20070021396A1 (es)
JP (1) JP2009501747A (es)
CN (1) CN101267827A (es)
BR (1) BRPI0614672A2 (es)
DE (1) DE102005034498A1 (es)
EC (1) ECSP088123A (es)
IL (1) IL188751A0 (es)
MX (1) MX2008000844A (es)
NO (1) NO20080824L (es)
NZ (1) NZ565829A (es)
PE (1) PE20070208A1 (es)
RU (1) RU2008105834A (es)
ZA (1) ZA200800373B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP2027855A1 (de) * 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
DE102007047608A1 (de) * 2007-10-04 2009-04-09 Grünenthal GmbH 19-nor-Progesterone zur Kontrazeption
WO2012058463A2 (en) 2010-10-27 2012-05-03 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9326997B2 (en) 2012-09-24 2016-05-03 Ahlam E. Elakkad Composition and method for treation Oligoovulation, Oligomenorrhea and Amenorrhea
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP6386711B2 (ja) * 2013-10-01 2018-09-05 任天堂株式会社 情報処理システム、サーバ装置、サーバプログラム及び情報処理方法
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
JP6759478B2 (ja) * 2019-02-13 2020-09-23 富士製薬工業株式会社 経口固形組成物、その製造方法、及びその製造方法によって得られた経口用錠剤

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2430953A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives 3,20-dioxo 4,9-diene 21-hydroxyle, leur procede de preparation et leur application comme medicaments
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
AU726091B2 (en) * 1996-07-26 2000-11-02 Wyeth Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
EP0921804B1 (en) * 1996-07-26 2003-09-10 Wyeth Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen
PT917466E (pt) * 1996-07-26 2004-12-31 Wyeth Corp Contraceptivo oral
US6511970B1 (en) * 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6190693B1 (en) * 1998-04-17 2001-02-20 Ortho-Mcneil Pharamceutical, Inc. Pharmaceutical methods of delivering folic acid
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
UA81423C2 (en) * 2002-08-15 2008-01-10 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
ATE409041T1 (de) * 2003-03-28 2008-10-15 Pantarhei Bioscience Bv Weibliche verhütungmethode und pharmazeutische zubereitungen die für eine solche methode geeignet sind
GB2402745B (en) * 2003-06-10 2005-08-24 Activeem Ltd Electromagnetic surveying for hydrocarbon reservoirs
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption

Also Published As

Publication number Publication date
US20100279989A1 (en) 2010-11-04
RU2008105834A (ru) 2009-08-27
US20070021396A1 (en) 2007-01-25
JP2009501747A (ja) 2009-01-22
NO20080824L (no) 2008-04-18
NZ565829A (en) 2012-01-12
IL188751A0 (en) 2008-12-29
BRPI0614672A2 (pt) 2012-12-04
PE20070208A1 (es) 2007-05-06
MX2008000844A (es) 2008-03-18
US20120028936A1 (en) 2012-02-02
ZA200800373B (en) 2009-08-26
DE102005034498A1 (de) 2007-01-25
CN101267827A (zh) 2008-09-17

Similar Documents

Publication Publication Date Title
ECSP088123A (es) Anticoncepcion oral con trimegestona
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
AR080912A1 (es) Formas de dosificacion solidas orales con dosis muy bajas para la hrt
AR032204A1 (es) Complejos de inclusion de ciclodextrina-drospirenona
BR0313921A (pt) Regime de reposição de estrogênio
CO6400186A2 (es) Tabletas de acetato de ulipristal
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
AR053803A1 (es) Uso de acido pinolenico
PE20061314A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
AR109263A2 (es) Composición que comprende moxidectina
UY30461A1 (es) Composicion farmacéutica para la anticoncepcion y para reducir el riesgo de malformaciones congénitas.
BRPI0311189B8 (pt) composições farmacêuticas contendo polimorfo a de flibanserin, bem como seu uso
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
GT200900296A (es) Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante.
ES2574999T3 (es) Método para la contracepción a demanda usando levonorgestrel o norgestrel
CO5650242A2 (es) Metodo para tratar hipotiroidismo
AR056674A1 (es) Anticoncepcion oral con trimegestona
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis
AR044831A1 (es) Forma de administracion inyectable de la flupirtina
AR057155A1 (es) Metodo de administracion de la 5-(2-clorofenil)-1,2-dihidro-7-fluor-8-metoxi-3-metil-pirazolo[3,4-b][1,4]benzodiazepina
ECSP099482A (es) Preparación farmacéutica para reducir la endometriosis